297 related articles for article (PubMed ID: 27278751)
1. Core-shell nanocarriers with high paclitaxel loading for passive and active targeting.
Jin Z; Lv Y; Cao H; Yao J; Zhou J; He W; Yin L
Sci Rep; 2016 Jun; 6():27559. PubMed ID: 27278751
[TBL] [Abstract][Full Text] [Related]
2. Co-delivery of paclitaxel and tetrandrine via iRGD peptide conjugated lipid-polymer hybrid nanoparticles overcome multidrug resistance in cancer cells.
Zhang J; Wang L; Fai Chan H; Xie W; Chen S; He C; Wang Y; Chen M
Sci Rep; 2017 May; 7():46057. PubMed ID: 28470171
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effect of iRGD-modified liposomes containing conjugated linoleic acid-paclitaxel (CLA-PTX) on B16-F10 melanoma.
Du R; Zhong T; Zhang WQ; Song P; Song WD; Zhao Y; Wang C; Tang YQ; Zhang X; Zhang Q
Int J Nanomedicine; 2014; 9():3091-105. PubMed ID: 25028548
[TBL] [Abstract][Full Text] [Related]
4. RGD peptide-modified, paclitaxel prodrug-based, dual-drugs loaded, and redox-sensitive lipid-polymer nanoparticles for the enhanced lung cancer therapy.
Wang G; Wang Z; Li C; Duan G; Wang K; Li Q; Tao T
Biomed Pharmacother; 2018 Oct; 106():275-284. PubMed ID: 29966971
[TBL] [Abstract][Full Text] [Related]
5. The influence of the penetrating peptide iRGD on the effect of paclitaxel-loaded MT1-AF7p-conjugated nanoparticles on glioma cells.
Gu G; Gao X; Hu Q; Kang T; Liu Z; Jiang M; Miao D; Song Q; Yao L; Tu Y; Pang Z; Chen H; Jiang X; Chen J
Biomaterials; 2013 Jul; 34(21):5138-48. PubMed ID: 23582684
[TBL] [Abstract][Full Text] [Related]
6. PEG-PLA nanoparticles modified with APTEDB peptide for enhanced anti-angiogenic and anti-glioma therapy.
Gu G; Hu Q; Feng X; Gao X; Menglin J; Kang T; Jiang D; Song Q; Chen H; Chen J
Biomaterials; 2014 Sep; 35(28):8215-26. PubMed ID: 24974009
[TBL] [Abstract][Full Text] [Related]
7. Co-Administration Of iRGD Enhances Tumor-Targeted Delivery And Anti-Tumor Effects Of Paclitaxel-Loaded PLGA Nanoparticles For Colorectal Cancer Treatment.
Zhong Y; Su T; Shi Q; Feng Y; Tao Z; Huang Q; Li L; Hu L; Li S; Tan H; Liu S; Yang H
Int J Nanomedicine; 2019; 14():8543-8560. PubMed ID: 31802868
[TBL] [Abstract][Full Text] [Related]
8. iRGD-paclitaxel conjugate nanoparticles for targeted paclitaxel delivery.
Hu H; Wang B; Lai C; Xu X; Zhen Z; Zhou H; Xu D
Drug Dev Res; 2019 Dec; 80(8):1080-1088. PubMed ID: 31411346
[TBL] [Abstract][Full Text] [Related]
9. Sustained release paclitaxel-loaded core-shell-structured solid lipid microparticles for intraperitoneal chemotherapy of ovarian cancer.
Han S; Dwivedi P; Mangrio FA; Dwivedi M; Khatik R; Cohn DE; Si T; Xu RX
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):957-967. PubMed ID: 30892967
[TBL] [Abstract][Full Text] [Related]
10. Development and evaluation of targeting ligands surface modified paclitaxel nanocrystals.
Sohn JS; Yoon DS; Sohn JY; Park JS; Choi JS
Mater Sci Eng C Mater Biol Appl; 2017 Mar; 72():228-237. PubMed ID: 28024581
[TBL] [Abstract][Full Text] [Related]
11. Core-shell structured gel-nanocarriers for sustained drug release and enhanced antitumor effect.
He W; Lv Y; Zhao Y; Xu C; Jin Z; Qin C; Yin L
Int J Pharm; 2015 Apr; 484(1-2):163-71. PubMed ID: 25724136
[TBL] [Abstract][Full Text] [Related]
12. Targeted lung cancer therapy: preparation and optimization of transferrin-decorated nanostructured lipid carriers as novel nanomedicine for co-delivery of anticancer drugs and DNA.
Shao Z; Shao J; Tan B; Guan S; Liu Z; Zhao Z; He F; Zhao J
Int J Nanomedicine; 2015; 10():1223-33. PubMed ID: 25709444
[TBL] [Abstract][Full Text] [Related]
13. Long-circulating self-assembled cholesteryl albumin nanoparticles enhance tumor accumulation of hydrophobic anticancer drug.
Battogtokh G; Kang JH; Ko YT
Eur J Pharm Biopharm; 2015 Oct; 96():96-105. PubMed ID: 26212785
[TBL] [Abstract][Full Text] [Related]
14. iRGD conjugated TPGS mediates codelivery of paclitaxel and survivin shRNA for the reversal of lung cancer resistance.
Shen J; Meng Q; Sui H; Yin Q; Zhang Z; Yu H; Li Y
Mol Pharm; 2014 Aug; 11(8):2579-91. PubMed ID: 24236909
[TBL] [Abstract][Full Text] [Related]
15. An optimized two-vial formulation lipid nanoemulsion of paclitaxel for targeted delivery to tumor.
Chen L; Chen B; Deng L; Gao B; Zhang Y; Wu C; Yu N; Zhou Q; Yao J; Chen J
Int J Pharm; 2017 Dec; 534(1-2):308-315. PubMed ID: 28986321
[TBL] [Abstract][Full Text] [Related]
16. Co-delivery of cisplatin and paclitaxel by folic acid conjugated amphiphilic PEG-PLGA copolymer nanoparticles for the treatment of non-small lung cancer.
He Z; Huang J; Xu Y; Zhang X; Teng Y; Huang C; Wu Y; Zhang X; Zhang H; Sun W
Oncotarget; 2015 Dec; 6(39):42150-68. PubMed ID: 26517524
[TBL] [Abstract][Full Text] [Related]
17. Redox-sensitive self-assembled nanoparticles based on alpha-tocopherol succinate-modified heparin for intracellular delivery of paclitaxel.
Yang X; Cai X; Yu A; Xi Y; Zhai G
J Colloid Interface Sci; 2017 Jun; 496():311-326. PubMed ID: 28237749
[TBL] [Abstract][Full Text] [Related]
18. Lipid nanocapsules: ready-to-use nanovectors for the aerosol delivery of paclitaxel.
Hureaux J; Lagarce F; Gagnadoux F; Vecellio L; Clavreul A; Roger E; Kempf M; Racineux JL; Diot P; Benoit JP; Urban T
Eur J Pharm Biopharm; 2009 Oct; 73(2):239-46. PubMed ID: 19560538
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel loaded folic acid targeted nanoparticles of mixed lipid-shell and polymer-core: in vitro and in vivo evaluation.
Zhao P; Wang H; Yu M; Liao Z; Wang X; Zhang F; Ji W; Wu B; Han J; Zhang H; Wang H; Chang J; Niu R
Eur J Pharm Biopharm; 2012 Jun; 81(2):248-56. PubMed ID: 22446630
[TBL] [Abstract][Full Text] [Related]
20. iRGD-modified lipid-polymer hybrid nanoparticles loaded with isoliquiritigenin to enhance anti-breast cancer effect and tumor-targeting ability.
Gao F; Zhang J; Fu C; Xie X; Peng F; You J; Tang H; Wang Z; Li P; Chen J
Int J Nanomedicine; 2017; 12():4147-4162. PubMed ID: 28615942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
